Transcriptome Analyses Revealed Adaptive-Responses in Livers of Mice Treated With Hua-Feng-Dan and Its “Guide Drug” Yaomu

Jia-Jia Liu
Zunyi Medical University

Ya Zhang
ZMU: Zunyi Medical University

Shang-Fu Xu
ZMU: Zunyi Medical University

Feng Zhang
Zunyi Medical University

Jing-Shan Shi
Zunyi Medical University

Jie Liu (✉ Jie@liuonline.com)
Zunyi Medical University  https://orcid.org/0000-0002-4530-1443

Research

Keywords: RNA-Seq, Hua-Feng-Dan, Yaomu, Liver transcriptome, Bioinformatics, GEO database correlation

DOI: https://doi.org/10.21203/rs.3.rs-143356/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Hua-Feng-Dan is a patent Chinese medicine for stroke recovery and is effective against Parkinson's disease models with modulatory effects on gut microbiota, but its effects on hepatic gene expression are unknown. This study used RNA-Seq to profile hepatic gene expression by Hua-Feng-Dan and its "Guide Drug" Yaomu.

Methods

Mice received orally Hua-Feng-Dan 1.2 g/kg, Yaomu 0.1-0.3 g/kg, or vehicle for 7 days. Liver pathology was examined, and total RNA was isolated for RNA-Seq. The bioinformatics, including GO and KEGG pathway enrichment analysis, two-dimensional clustering, Ingenuity Pathways Analysis (IPA), and Illumina BaseSpace Correlation Engine were used to analyze differentially expressed genes (DEGs). qPCR was performed to verify selected genes.

Results

Hua-Feng-Dan and Yaomu did not produce liver toxicity as evidenced by histopathology and serum ALT and AST. GO Enrichment revealed Hua-Feng-Dan affected lipid homeostasis, protein folding and cell adhesion. KEGG showed activated cholesterol metabolism, bile secretion and PPAR signaling pathways. DEGs were identified by DESeq2 with \( p < 0.05 \) compared to controls. Hua-Feng-Dan produced 806 DEGs, Yaomu-0.1 had 235, and Yaomu-0.3 had 92 DEGs. qPCR on selected genes largely verified RNA-Seq results. IPA upstream regulator analysis revealed activation of MAPK and adaptive responses. Yaomu-0.1 had similar effects, but Yaomu-0.3 had little effects. Hua-Feng-Dan-induced DEGs were highly correlated with the GEO database of chemical-induced adaptive transcriptome changes in the liver.

Conclusion

Hua-Feng-Dan at clinical dose did not produce liver pathological changes but induced metabolic and signaling pathway activations. Low dose of its Guide Drug Yaomu produced similar changes to a lesser extent, but high dose of Yaomu had little effects. The effects of Hua-Feng-Dan on liver transcriptome changes may produce adaptive responses to program the liver to produce beneficial or detrimental (over-dosed) pharmacological effects.

Background

Hua-Feng-Dan has over 300 years of history in the treatment of stroke and various diseases in China, and is still used today alone or in combination with other medications [1]. Hua-Feng-Dan contains cinnabar (HgS) and realgar (As\(_4\)S\(_4\)), and our initial research focused on safety evaluation of Hua-Feng-Dan following acute [2], subacute [3, 4], and subchronic [5, 6] administrations, and demonstrated that the toxicity of Hua-Feng-Dan is different from environmental mercury (Hg) and arsenic (As) compounds [1].
In addition to cinnabar and realgar, Hua-Feng-Dan also contains plants (herbs), including *Gastrodia elata* Bl.; *Nepeta tenuifolia* Benth; *Croton tiglium* L.; *Atractylodes lancea* (Thumb.) DC.; *Typhonium giganteum* Engl.; *Blumea balsamifera* (L.) DC.; *Acorus tetarinowii* Schott; *Perilla frutescens* (L.) Britt. Hua-Feng-Dan also contains animal-based products (*Moschus berezovskii* Flerov (Shexiang); *Buthus martensii* Karsch (Quanxie), *Bombyx mori* Linnaeus (Jiangcan), and other minerals (Borax; Borneolum Syntheticum) [1]. Network pharmacology has found β-sitosterol, luteolin, baicalein, wogonin and cinnabar are potential active ingredients [7]. In an attempt to examine the pharmacological basis of this traditional medicine, we have used experimental animal models to demonstrate the protective effects of Hua-Feng-Dan against LPS plus MPTP induced Parkinson’s disease (PD) mouse model [6], and LPS plus rotenone-induced PD neurodegeneration rat model [5], and identified cinnabar and realgar are two active ingredients in the recipe both in LPS-induced neuroinflammation in rat midbrain neuron-glia co-cultures [8] and in LPS plus rotenone induced neuroinflammation and dopaminergic neuron loss in rats [5]. We have also found Hua-Feng-Dan exert beneficial effects on gut microbiota in normal mice [9], in PD mice [6], and in PD rats [5].

Yaomu is considered as the “Guide Drug” in Hua-Feng-Dan. “Guide drug” is an important theory in Chinese medicines as exemplified by Licorice (also called Gan-Cao, *Glycyrrhiza uralensis* Fisch). Licorice as a “Guide Drug” is essential to enhance efficacy and reduce toxicity when combined with other herbal medicine preparations [10, 11]. Yaomu in Hua-Feng-Dan consists of 7 components (*Typhonium giganteum* Engl; *Pinellia ternata* (Thunb.) Breit; *Arisaema heterophyllum* Blume; *Aconitum carmichaelii* Debx; *Curcuma wenyujin* Y. H. Chen et C.Ling; Medicated Leaven (Shen-Qu); and cow bile water), and is subjected to fermentation for three months. Fermentation is an important processing technology in traditional medicines under appropriate temperature, humidity, and microorganisms to reduce toxicity, enhance efficacy, and generate active inter-metabolites [12, 13]. Limited studies on Yaomu in Hua-Feng-Dan are found in regard to processing technology [14], and fermented Yaomu could reduce the content and toxicity of aconitine, mesaconitine, and hypaconitine [15]. However, little is known about hepatic effects of Yaomu.

The liver is the main organ of the phase I and phase II drug metabolism and plays a leading role in the elimination of oral drugs [16]. The liver is also an important organ of detoxification in response to xenobiotics. To “program the liver” is an important concept in that xenobiotics at appropriate doses could evoke adaptive responses to protect against environmental and external damage, and to induce a number of molecular events to exert beneficial effects against various disorders [16]. The use of traditional medicines to modulate innate and adaptive immune functions has been reviewed [17]. Oleanolic acid, a triterpenoid from many herbs/fruits, could reprogram the liver to protect against a variety of hepatotoxicants at the low doses, but is hepatotoxic at higher doses [18]. Thus, learn to program the liver would help us to understand the beneficial or harmful effects of traditional medicines such as Hua-Feng-Dan.

RNA-seq is an advanced technology for high-throughput analysis of mRNA, small RNA, and non-coding RNA, etc. RNA-Seq is also superior to microarray for genomic profiling [19], and has been recommended to study traditional Chinese medicines [20]. Therefore, this study utilized RNA-Seq to profile the liver
transcriptome after Hua-Feng-Dan and Yaomu treatment. After quality evaluation of RNA-Seq analysis data, differentially expressed genes (DEGs) were identified with the DESeq2 method compared to controls. A comprehensive bioinformatics including two-dimensional clustering, GO and KEGG pathway enrichment analysis, ingenuity pathways analysis (IPA), and Illumina BaseSpace Correlation Engine (BSCE) were used to analyze DEGs and to mine adaptive response changes.

**Material And Methods**

**Hua-Feng-Dan and its “Guide Drug” Yaomu**

Hua-Feng-Dan (HFD) and its Guide Drug Yaomu (YM) were provided by Hua-Feng-Dan Pharmaceutical Co. (Guizhou, China). Yaomu is the most important part of the traditional medicine Hua-Feng-Dan [15], and fermented for three months before using as the “Guide Drug” to make Hua-Feng-Dan with other herbs, animal-based products, and minerals as listed in Introduction and reported previously [1, 5–8].

**Animal and drug treatment**

Adult male C57BL/6J mice (20–22 g) were obtained from the SPF (Beijing) Biotechnology Co., Ltd (certificate No. SCXK,2101-0011). The experimental animals were kept in the SPF animal room of the Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University, at a temperature of 20 ± 2 °C, lighting from 8:00 in the morning to 8:00 in the evening, and free access to food and water. The experimental protocol followed the Chinese Animal Protection and Welfare Guidelines and was approved by the Animal Ethics Committee of Zunyi Medical University (2015-07).

After acclimatization for one week, mice were randomly divided into four groups: Control group (n = 5), YM-0.1 (n = 5, Yaomu 0.1 g/kg), YM-0.3 (n = 7, Yaomu 0.3 g/kg), HFD (n = 5, Hua-Feng-Dan 1.2 g/kg). Mice received oral gavage daily for 7 consecutive days; the dose of Hua-Feng-Dan selection was based on recent publications [5, 6], and Yaomu was estimated from the recipe. Twenty-four hours after the last administration, mice were anesthetized, blood and livers were collected.

**Histopathology**

A portion of livers from the same site was cut and fixed with 10% formaldehyde, dehydrate with ethanol gradients, and embed in paraffin. Liver tissue was cut into 4 µm slices with a tissue slicer (model: RM2245), sections were deparaffinized with xylene, hydrated with gradient ethanol, stained with conventional HE, and observed under upright optical microscope (Olympus, Tokyo, Japan).

**Biochemical Analysis**

After the mice were anesthetized, the blood was collected and left standing at room temperature for 2 hours and centrifuged at 3500 rpm for 10 min to collect the serum. The ALT and AST test kits were used to detect the activity of ALT and AST in serum (Nanjing Jiancheng Institute of Bioengineering, Nanjing, China).
RNA extraction

Total RNA was extracted from mouse liver tissues using RNAiso plus (TAKARA, Dalian, China). The concentration of total RNA is measured with ND-2000 nanodrop, with A260 /A280 > 1.8.

RNA-Seq

The EASY RNA-Seq method was used to complete the construction of the sample library, and after quality control testing, the Illumina platform was used for sequencing by Chongqing Weilang Biotechnology Co., Ltd. (Chongqing, China). Briefly, RNA is subjected to reverse transcription reaction with oligo(dT) primer to generate the first-strand cDNA; through the joint reaction of RNase H enzyme, DNA polymerase and T4 ligase, double-strand cDNA was generated. The Agencourt AMPure XP Beads were used to purify cDNA by magnetic separation. After the double-stranded cDNA is fragmented by Tn5 enzyme, the RD sequence required for sequencing is added to both ends, and then P5 and P7 are connected to the RD sequence according to the TruePrep DNA Library Prep Kit with P5/P7 adapter primers (Vazyme, cat. TD503). Sequencing primers were at both ends, and PCR was amplified by VAHTS™ DNA clean beads kit (Vazyme, cat. N411-02). The Illumina HiSeq platform with a 150 bp double-ended model was used for sequencing analysis.

Bioinformatics

RNA-Seq generated fragments per kilobase of exon per million fragments mapped (FPKM) were transformed to raw gene counts for quality control analysis with all parameters performed by the sequencing company (Chongqing Weilang Biotechnology Co., Ltd., China). The initial bioinformatics analysis was also performed by including two group comparisons using DESeq2 methods, GO, and KEGG analysis with company service.

Gene ontology (GO) and KEGG pathway enrichment analysis. The differentially expressed genes between the two groups were analyzed by Gene Ontology (GO) enrichment, and the hypergeometric distribution was used to test the significantly enriched GO entries. ClusterProfiler software [21] was used to analyze the Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway enrichment of differentially expressed genes between groups. Use bubble charts to visualize the top functional pathways in the analysis results of GO and KEGG enrichment (p-value < 0.05). The size of the dot in the figure represents the number of differential genes that can be annotated in the functional pathway, and the shade of the color represents the significant degree of enrichment of the functional pathway. Rich factor is a score used to evaluate the degree of enrichment of the functional pathway.

Two-dimensional clustering. The Gene Cluster version 3.0 (https://cluster2.software.informer.com/3.0/) was used to generate hierarchical complete linkage of DEGs, and the generated .cdt file was then uploaded into TreeView (https://treeview.software.informer.com/1.6/) to generate the heatmap for visualization.
Ingenuity Pathway Analysis. Ingenuity Pathway Analysis (IPA) server (Qiagen, Redwood City, CA) was used to perform upstream regulators analysis. DEGs ($p < 0.05$) from HFD, YM-0.1, YM-0.3 treatments vs control, respectively were subjected to IPA Core Analysis, followed by Comparative Analysis to compare the Z-score of the changes among treatment groups.

BaseSpace Correlation Engine analysis. BaseSpace Correlation Engine (BSCE, Illumina, CA) is the RNA sequencing and microarray database curated over 23,000 scientific studies to get data-driven answers for genes, experiments, drugs and phenotypes for the research. DEGs from various treatment groups vs Controls were uploaded to BSCE and compared with all biosets in the database using the Running Fisher test. This method provides an assessment of the statistical significance of the correlation of the overlapping genes between each treatment DEGs and biosets curated in BSCE, with a summary p-value. The results were exported, and each p-value was converted to a -log(p-value). Biosets with -log(p-value) + 4 or -4 were considered significant correlation [22]. A column in the gene expression spreadsheet was populated with the -log(p-value) for each bioset. Biosets that were positively correlated with the DEGs were predicted to produce similar effects, either directly or indirectly; biosets that were negatively correlated were predicted to suppress the biological responses.

Real-time qPCR. The total RNA was reverse transcribed with 5 x PrimeScripe Buffer, PrimeScript RT Enzyme MIX, Oligo dT Primer and Random 6 mers. The iTaq™ Universal SYBR green PCR Super Mix (BIO-RAD) was used for real time qPCR analysis. The reaction parameters were 95 °C 3 min, 95 °C 10 s, 60 °C 45 s, 40 cycles in total. The Ct values were normalized to β-actin of the same sample and calculated by the $2^{-\Delta\Delta Ct}$ method and expressed as percentage of Control. The primers were designed by Primer3 (version 4), and synthesized by Shanghai Sangon Biotech as described [6].

Statistical Analysis

The DESeq2 method was used to compare differences between two groups, and the criteria were set at $p < 0.05$. For real time qPCR analysis, the data presented were mean ± SEM. The Normality Test (Shapiro-Wilk) was first performed. Kruskal-Wallis one-way AONVA was performed, followed by Dunn's multiple range test (SigmaPlot v14), the significance was set at $p < 0.05$.

Results

The effect of Hua-Feng-Dan and Yaomu on serum enzyme activities and liver pathology

Seven days after administration, the body weight of mice in each group increased slightly (The initial weights were 22.52 ± 0.51, 22.12 ± 1.16, 23.06 ± 1.28, 23.28 ± 0.68 g for Control, Yaomu-0.1, Yaomu-0.3, and Hua-Feng-Dan groups, respectively; the final weights were 23.64 ± 1.08, 23.3 ± 1.06, 23.9 ± 1.15, 24.74 ± 0.66 g for Control, Yaomu-0.1, Yaomu-0.3, and Hua-Feng-Dan groups, respectively). All mice were in good health, the hair is shiny, there is no hair loss, the intake of diet and water is normal, and there were no other abnormal phenomena. Compared with the Control group (ALT, 14.5 ± 0.73IU/L; AST, 19.0 ± 2.21 IU/L), there was no significant difference in serum ALT and AST of mice in Yaomu-0.1 group (ALT, 13.9 ±
2.66 IU/L; AST, 23.2 ± 1.09 IU/L), Yaomu-0.3 group (ALT, 13.8 ± 3.06 IU/L; AST, 16.7 ± 3.62 IU/L) and Hua-Feng-Dan group (ALT, 22.3 ± 8.70IU/L; AST, 20.0 ± 6.59 IU/L). This result showed that Hua-Feng-Dan and Yaomu at the clinical dose did not cause hepatic toxicity.

The liver lobules of the mice in the Control group and treatment groups were clear and complete, without degeneration and necrosis of hepatocytes, and the liver cords were arranged radially around the central vein. No obvious pathological damage was observed in the liver after administration of different doses of Yaomu (YM) and Hua-Feng-Dan (HFD) to mice (Fig. 1).

**Gene Expression Pattern overview**

The results (~22500/sample) obtained from RNA-Seq FPKM were transformed to gene raw counts, and then subjected to cluster analysis. The clustering heatmaps of gene expressions from 12 individual samples (Fig. 2A) and 4 groups (Fig. 2B) are shown. Red represents the up-regulation; blue represents the down-regulation. The color brightness is associated with differences. Fig. 2A shows the heatmap of 12 individual samples. Some of the three samples in each group showed similar patterns (L-1, L-2 and L-3, Control group; L-7, L-8 and L9, YM-H group), while in YM-L group, L-5 was somewhat different from L-4, and quite different from L6. In Hua-Feng-Dan (HFD) group, L-11 was separated from L-10 and L-12. Fig. 2B shows the heatmap of 4 groups, YM-L was separated from others, and YM-H was slightly different from Control; and Hua-Feng-Dan (HFD) had clear pattern different from Control.

**GO and KEGG pathway enrichment analysis**

The GO database standardizes the description of differentially expressed genes in terms of function, participating biological pathways, and cell location. The KEGG is a database of the metabolic pathways of gene products in cells and the functions of these gene products. Here we focus on the comparison between Hua-Feng-Dan and Control group. Figure 3 summarizes the top 20 enriched by GO and the top 7 enriched by KEGG pathway. GO Enrichment Analysis shows that the biological process of differentially expressed genes was mainly involved in lipid metabolism, sterol homeostasis, cholesterol homeostasis, intestinal absorption, protein folding and cell adhesion (Figure 3A). KEGG Enrichment Analysis shows that pathways of differentially expressed genes were mainly involved in cholesterol metabolism, bile secretion, PPAR signaling pathway, drug metabolism, fat digestion and absorption, retinol metabolism and the like (Figure 3B).

**Differentially Expressed Gene Analysis**

Differentially expressed genes (DEGs) were analyzed via the DESeq2 method compared to Controls. DEGs were set at \( p < 0.05 \). Using complete clustering, the DEGs were clustered and input into Treeview to visualize the differences between groups (red indicates up-regulation and blue indicates down-regulation). From Figure 4, compared to Hua-Feng-Dan group (806 DEGs), YM-L group had 235 DEGs and YM-H group had 92 DEGs. Four clusters were selected for annotation (two upregulated: line 42-150, 109 genes increased in HFD and YM-L group only, involved in cellular function and signal regulation; line 151-
179, 28 genes involved in cellular function, circadian, and signal transduction were increased in all three groups. Two downregulated cluster: line 494-556, 63 genes decreased in HFD and YM-L group only, while line 557-567, 11 genes decreased in all three groups. These genes are involved in Phase-I, II, and III metabolism and immunomodulation. The clustered DEGs with the annotation for gene names are shown in Supplementary Table 1.

**qPCR analysis of selected DEGs**

Selected 10 DEGs were further analyzed via real time qPCR (Figure 5). The expression of Cyp2a4 was increased 2.2-fold by Hua-Feng-Dan (HFD), but was unaffected by YM-0.1 and YM-0.3; the expression of Cyp4a14 was increased 2.3-fold by HFD, YM-0.1 and 0.3 did not affect its expression. The expression of Fgf21 was increased by HFD (3.7-fold), although not reaching significance; the expression of Gm3776 was increased 6.5-fold by HFD; The expression of Mt2 (10-fold) and Gsta1 (4.7-fold) was increased by HFD. The expression of Il1r1 (24-fold) and Egr1 (8.9-fold) was increased by HFD. The expression of Trib3 (1.7-fold) and Bcl2a1d (1.7-fold) was tended to increase, but not significant. The two doses of YM had little effects on the expression of these genes.

**Ingenuity Pathways Analysis of DEGs**

The IPA upstream regulator analysis (Figure 6) was used to identify the upstream regulators that may be responsible for gene expression changes observed in the study. IPA predicts which upstream regulators are activated or inhibited to explain the up-regulated and down-regulated genes observed. The top 25 upstream regulators were selected, including 18 increased by Hua-Feng-Dan with molecules (Tgf beta; NRG1; Vegf; NFkB (complex); JUN; STAT3; CREB1; P38 MAPK; CHUK; EGR1; ERK1/2; and EP300) or with chemicals (Tretinoin; carbon tetrachloride; decitabine; ursodeoxycholic acid; AGN194204 and 4-hydroxytamoxifen). The 7 downregulated regulators were molecules (Let-7a-5p, ACOX1, and DICER1) and chemicals (MEK1/2 inhibitor U0126; p38 MAPK inhibitor SB203580; JNK inhibitor SP600125; and PIK3 inhibitor LY294002). All of these upstream regulators point towards activation of MAPK signaling pathways and adaptive responses with the downregulation of inhibitors for MAPK and PIK3 signaling pathways. YM-0.1 produced similar upstream regulator alternations in the similar direction, except for ursodeoxycholic acid; while the high dose of YM (0.3g/kg) produced weak alterations in these regulators, with 3 in opposite directions (different color).

**Illumina BaseSpace Correlation Engine analysis of DEGs**

All the biosets were imported into BSCE for curated studies, filtered by mice, RNA expression and treatment vs control, and the curated files were exported and the -log (p-values) were calculated and the VLOOKUP function was used for correlation comparison with the GEO database. There were very high correlations between HFD-induced DEGs and 25 GSE databases with -log(p-values) from 12 to 26.9 (Figure 7). The deeper the red color, the higher -log (p-values), and the values >4 is considered significant [22]. YM-0.1 moderately correlated with 18 GSE databases in the same direction but to the lesser extent, while YM-0.3 only weakly correlated with 9 databases, and negatively correlated with 3 databases (blue
Thus, Hua-Feng-Dan at the clinical dose mimics chemical-induced adaptive responses, while YM-0.1 could mimic some effects of HFD, but YM-0.3 has little effect, suggesting that the use of Yaomu at appropriate doses is important to induce adaptive responses.

**Discussion**

This study demonstrated that Hua-Feng-Dan and its “Guide Drug” Yaomu at clinical doses did not produce damage to the liver but produced gene expression changes. RNA-Seq revealed 806 DEGs in Hua-Feng-Dan-treated livers compared to controls, and low-dose of Yaomu produced 235 DEGs in the same direction. GO and KEGG analysis revealed Hua-Feng-Dan affected metabolism and singling pathways. IPA upstream analysis pointed towards activation of MAPK signaling pathways and adaptive responses by Hua-Feng-Dan. qPCR verified 10 selected DEGs. Hua-Feng-Dan induced gene expression changes were highly correlated with the GEO database of chemical-treated livers of mice, and Yaomu-0.1 had similar effects, but to a lesser extent. This RNA-Seq study clearly demonstrated Hua-Feng-Dan and low dose of Yaomu induced adaptive responses to reprogram the liver for biological effects as seen in Chinese medicine formulas, or in Chinese medicine extracts such as oleanolic acid [16-18].

We have shown that cinnabar (HgS)-containing Hua-Feng-Dan is different from environmental mercury compounds (HgCl₂, MeHg) in producing liver injury [2, 3]. In the present study, Hua-Feng-Dan and Yaomu at clinical doses also did not produce liver injury as evidenced by serum enzyme activities and histopathology, consistent with prior observations. This is an important pre-requirement for RNA-Seq experiments and results interpretation to help us understand how Hua-Feng-Dan could program the liver to produce adaptive responses as seen with oleanolic acid, an active ingredient of many Chinese medicines [16, 18].

GO and KEGG pathway enrichment analysis showed the top 20 of GO enrichment and the top 7 of KEGG pathway enrichment. For example, high-fat, high-energy diets can increase the incidence of lipid metabolism disorders [23], and lipid transport disorders can cause lipid accumulation in liver cells, leading to fatty liver [24]. The effects of Hua-Feng-Dan on lipid metabolism could produce adaptive or detrimental effects. For the KEGG pathways, cholesterol metabolism was at the top. Cholesterol is essential for maintaining membrane fluidity and is regulated by nuclear receptors [25] and cholesterol homeostasis is important for biological functions and bile acid synthesis [26, 27]. The effects of Hua-Feng-Dan on cholesterol metabolism and bile acid homeostasis could be important adaptive responses. Peroxisome proliferation-activated receptors (PPARs) regulate the lipid metabolism and cellular immune and biological functions [28], and effects of Hua-Feng-Dan on PPAR signaling pathway and drug metabolism genes are important to program the liver. Retinoid metabolism and signaling are necessary to maintain immunity, cell proliferation and differentiation [29], which was affected by Hua-Feng-Dan. All these changes imply the ability of Hua-Feng-Dan to program the liver.

Two-dimensional clustering analysis of DEGs showed that Hua-Feng-Dan upregulated genes of cellular function, signal regulation, circadian, and signal regulation; reduced the expression of genes related to
Phase-I, II and III xenobiotic metabolism, endogenous metabolism, disease traits, and immune modulation, all point towards adaptive responses. However, the dose and duration of administration could differentiate the adaptive response from toxicity [16-18]. Yaomu as the “Guide Drug” of Hua-Feng-Dan [14, 15] produced similar effects, but to a lesser extent. The change pattern of DEGs in low-dose Yaomu (0.1 g/kg) is more similar to that of Hua-Feng-Dan, while high-dose Yaomu (0.3 g/kg) is less effective, suggesting appropriate dose of Yaomu could be important for pharmacological effects of Hua-Feng-Dan.

Based on Two-dimensional clustering and fold changes, 10 DEGs were selected for qPCR verification. In general, the qPCR results matched the RNA-Seq results. Hua-Feng-Dan induced Cyp2a4 (2.2-fold), Gm3776 (6.5-fold), Mt2 (10-fold), Gsta1 (4.7-fold), Il1rn (24-fold) and Egr1 (8.9-fold). Cyp2a4 is sensitive to circadian regulation and plays roles in liver detoxification [30]; Overexpression of Cyp4a14 induced by hyperoxia contributes to increased resistance to oxidative stress [31]; Fgf21 is a metabolic regulator with multiple physiologic functions and is a novel biomarker for non-alcoholic fatty liver disease (NAFLD) in humans and limits hepatotoxicity in mice [32]; Gm3776 is a CAR-target gene in liver of mice as an adaptive responses to xenobiotics [33]; Metallothioneins (Mt2) are sulfhydryl-rich small proteins for heavy metal detoxification and free radical scavenging as a cellular antioxidant [34]; Glutathione S-transferase A1 (Gsta1) is a phase II enzymes playing adaptive against toxic stimuli [35]; Interleukin-1 receptor antagonist (Il1rn) is a member of the interleukin 1 cytokine family, inhibits the activities of interleukin 1α (IL-1α) and interleukin 1β (IL-1β), and prevent IL-1β overexpression during inflammatory responses [36]; Early growth response 1 (Egr1) is induced during liver injury and is an important acute-phase adaptive protein [37]; Tribbles Pseudokinase 3 (Trib3) plays an important roles in cellular stress and metabolism, and its induction is considered as an adaptive response [38]; Bcl2a1d is a member of the bcl2 protein family and acts as anti- and pro-apoptotic regulators that are involved in a wide variety of cellular activities [39]. Up-regulation of these genes points towards the adaptive machinery is activated by Hua-Feng-Dan and low dose of Yaomu to a less extent, in an attempt to program the liver to produce pharmacological effects.

IPA analysis of upstream regulatory factors helped our further understanding of Hua-Feng-Dan induced DEGs and pathway alterations. The top 25 upstream regulators clearly indicated the activation of the MAPK signaling pathways. For example, Transforming growth factor beta (Tgf beta) regulates cell fate decisions during embryonic development, tissue homeostasis and regeneration [40]. Neuregulin 1 (NRG1) is a cell adhesion molecule that plays an important role in regulating tissue development, growth and homeostasis [41]. Vascular endothelial growth factor (Vegf) is a sub-family of growth factors, and mediates liver and ischemic injury [42]. Nuclear factor kapa B (NF-κB) is a protein complex that controls transcription of DNA, cytokine production and cell survival, and plays an important role in adaptive immune response [43]. Signal transducer and activator of transcription 3 (STAT3) regulates hepatocyte proliferation and homeostasis [44]. P38 mitogen-activated protein kinases are a class of mitogen-activated protein kinases (MAPKs) that are responsive to stress stimuli [45]. ERK1/2 are broadly expressed protein kinases that are involved in proliferation, differentiation, motility, and cell death [46]. These upstream molecules imply that the adaptive machinery is activated. On the other hand, the
downregulation of the PI3K inhibitor LY294002 [47], p38 MAPK inhibitor SB203580 [48], and MEK1/2 inhibitor U0126 [49] further facilitated the activation of these adaptive responses. A network pharmacology analysis of anti-stroke effects of Hua-Feng-Dan revealed potential molecular targets [7], and some of the regulated molecules coincide with the adaptive responses induced by Hua-Feng-Dan.

To further identify biological significance of Hua-Feng-Dan-induced DEGs, the keyword “treatment vs control” and “mice” was used to curate biosets in the GEO database. The -log(p-value) was used to evaluate the correlation of the database with Hua-Feng-Dan-induced DEGs [22]. The larger the -log(p-value), the higher degree of similarity. For example, treatment of CD-1 mice for 4 days with 1,4-dichlorobenzene (GSE 44783) [50] had a -log(p-value) of 26.9 for Hua-Feng-Dan; Fed mice with soybean oil-rich high fat diet (GSE68360) [51] had a -log(p-value) 26.4 for Hua-Feng-Dan; Fed mice with luteolin could reprogram the liver to ameliorate deleterious effects of diet-induced obesity (GSE54189) [52] had a -log(p-value) of 20.7 with Hua-Feng-Dan. Glucose sensing is required to preserve B cell glucose competence (GSE43581) [53] had a -log(p-value) of 17.3 with Hua-Feng-Dan. Effects of unfolded proteins in the endoplasmic reticulum (ER stress) on glucose intolerance in eIF2 (alphaP) transgenic mice gene profiling (GSE11210) [54] had a -log(p-value) of 14.5 with Hua-Feng-Dan. Fed Clock mutant mice with bezafibrate, a PPARα activator, affected circadian clock, lipid metabolism and liver gene expression (GSE20512) [55] had a -log(p-value) of 14.2 with Hua-Feng-Dan. Non-genotoxic carcinogen and peroxisome proliferator diethylhexylphthalate (DEHP)-treated mice showed hepatic gene expression changes associated with multiple biological functions, including complement activation, hemostasis, the endoplasmic reticulum overload response, and circadian rhythm (GSE55733) [56] had a -log(p-value) of 12.9 with Hua-Feng-Dan. Thus, Hua-Feng-Dan at clinical dose evoked hepatic gene expression changes towards adaptive responses, which was mimicked by the low dose of Yaomu to a lesser extent, but high dose of Yaomu was ineffective. These changes could be beneficial or detrimental, similar to the ability of oleanolic acid to program the liver to protect against various hepatotoxicants, but is hepatotoxic at high doses [18]. Caution should be taken when using Hua-Feng-Dan at the high dose and long-term administration.

**Conclusions**

This study profiled Hua-Feng-Dan and its "Guide Drug" Yaomu on liver gene expression by RNA-Seq. Hua-Feng-Dan and Yaomu at clinical dose did not cause liver toxicity, but induced differential gene expression reflecting adaptive responses to program the liver. Low dose of Yaomu produced similar, but less changes compared to Hua-Feng-Dan, while the high dose of Yaomu had little effect, suggesting that appropriate dose of Yaomu is important. Effects of Hua-Feng-Dan on the liver transcriptome changes were significantly correlated with chemical-induced adaptive responses in the livers of mice from the GEO database. Thus, Hua-Feng-Dan could induce adaptive responses to reprogram the liver to produce biological effects, which could be beneficial at appropriate doses, or harmful with high doses and longer time of administration.


Abbreviations

HFD, Hua-Feng-Dan,

YM, Yaomu

GO, Gene ontology

KEGG, Kyoto Encyclopedia of Gene and Genomes

IPA, Ingenuity Pathway Analysis

BSCE, BaseSpace Correlation Engine (Illumina)

Declarations

Author contributions

Jie Liu and Shang-Fu Xu conceptualized the experiment. Jia-Jia Liu performed animal studies. Jia-Jia Liu and Ya Zhang performed bioinformatics analysis and qPCR experiments. Jia-Jia Liu and Jie Liu drafted the manuscript, Shang-Fu Xu, Feng Zhang and Jing-Shan Shi critically reviewed and edited the manuscript. All authors reviewed and approved the final version of the manuscript. Shang-Fu Xu and Jie Liu were the co-corresponding authors.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81760658; 81560592, 82060817).

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate

Experiments were approved by the Ethics Committee on Animal Experiments of Zunyi Medical University

Consent for publication

Not applicable.

Competing interest

All authors declared no conflict of interest.
Acknowledgement

The authors would like to thank Prof Qin Wu and Mrs. An-Ling Hu for their help on this work.

References

1. Liu J, Wei LX, Wang Q, Lu YF, Zhang F, Shi JZ, Li C, Cherian MG: A review of cinnabar (HgS) and/or realgar (As(4)S(4))-containing traditional medicines. J Ethnopharmacol 2018, 210:340-350.

2. Yan JW, Miao, J.W., He, H.Y., Shi, J.Z., Wu, Q., Liu, J., Shi, J.S.,: Comparative study of hepatotoxicity and nephrotoxicity produced by Wan-Sheng-Hua-Feng Dan, relagar and cinnabar. Chin J Pharmacol Toxicol 2011, 25:380-385.

3. Peng F, Yang H, Wu Q, Liu J, Shi J: [Studies on subacute toxicity of Wansheng Huafeng Dan in rats]. Zhongguo Zhong Yao Za Zhi 2012, 37(7):1017-1022.

4. Zhu QN, Lu YF, Shi JZ, Wu Q, Zhang F, Shi JS, Liu J: [Distinct effect of Wansheng Huafeng Dan containing ardisia crenata on renal transporters, mercury accumulation and Kim-1 expression from mercuric chloride]. Zhongguo Zhong Yao Za Zhi 2014, 39(10):1892-1896.

5. Chen C, Zhang BB, Hu AL, Li H, Liu J, Zhang F: Protective role of cinnabar and realgar in Hua-Feng-Dan against LPS plus rotenone-induced neurotoxicity and disturbance of gut microbiota in rats. J Ethnopharmacol 2020, 247:112299.

6. Hu AL, Song S, Li Y, Xu SF, Zhang F, Li C, Liu J: Mercury sulfide-containing Hua-Feng-Dan and 70W (Rannasangpei) protect against LPS plus MPTP-induced neurotoxicity and disturbance of gut microbiota in mice. J Ethnopharmacol 2020, 254:112674.

7. Yang P, He H, Xu S, Liu P, Bai X: Potential Molecular Target Prediction and Docking Verification of Hua-Feng-Dan in Stroke Based on Network Pharmacology. Evid Based Complement Alternat Med 2020, 2020:8872593.

8. Zhang F, Lu Y, Wu Q, Yan J, Shi J, Liu J: Role of cinnabar and realgar of WSHFD in protecting against LPS-induced neurotoxicity. J Ethnopharmacol 2012, 139(3):822-828.

9. Liu Y, Xu, SF, Zhang, F, Shi, JS, Cheng, ML, Liu, J: Cinnabar-containing Chinese medicine Hua-Feng-Dan differs from mercury sulfide and mercury chloride in affecting gut microbiota in mice. F1000Res 2021:(accepted).

10. Jiang M, Zhao S, Yang S, Lin X, He X, Wei X, Song Q, Li R, Fu C, Zhang J et al: An "essential herbal medicine"-licorice: A review of phytochemicals and its effects in combination preparations. J Ethnopharmacol 2020, 249:112439.

11. Wang X, Zhang H, Chen L, Shan L, Fan G, Gao X: Liquorice, a unique "guide drug" of traditional Chinese medicine: a review of its role in drug interactions. J Ethnopharmacol 2013, 150(3):781-790.

12. Li L, Wang L, Fan W, Jiang Y, Zhang C, Li J, Peng W, Wu C: The Application of Fermentation Technology in Traditional Chinese Medicine: A Review. Am J Chin Med 2020, 48(4):899-921.
13. Zhang LX, Gao WY, Wang HY: [Review of traditional Chinese medicine processed by fermentation]. Zhongguo Zhong Yao Za Zhi 2012, 37(24):3695-3700.

14. Cao G.Q. ZYP, Huang H.B.: Study on drying technology of HuaFeng Pill Drug. Zhongguo Mingzu Yiyao ZaZhi 2012, 7:38-40.

15. Cao G. ZY, Xu J., Gao L., Liao X.: Effects of cattle bile on reducing toxicity of Huafeng Pills medicine fermentation. Zhong Cheng Yao 2019, 41(4):868-873.

16. Klaassen CD: Learning to program the liver. Annu Rev Pharmacol Toxicol 2014, 54:1-8.

17. Ma HD, Deng YR, Tian Z, Lian ZX: Traditional Chinese medicine and immune regulation. Clin Rev Allergy Immunol 2013, 44(3):229-241.

18. Liu J, Lu YF, Wu Q, Xu SF, Shi FG, Klaassen CD: Oleanolic acid reprograms the liver to protect against hepatotoxicants, but is hepatotoxic at high doses. Liver Int 2019, 39(3):427-439.

19. Rao MS, Van Vleet TR, Ciurlionis R, Buck WR, Mittelstadt SW, Blomme EAG, Liugiuri MJ: Comparison of RNA-Seq and Microarray Gene Expression Platforms for the Toxicogenomic Evaluation of Liver From Short-Term Rat Toxicity Studies. Front Genet 2018, 9:636.

20. Wang XY, Song JY, Xie CX, Han JP, Chen SL: [RNA-Seq and genuine traditional Chinese medicine]. Yao Xue Xue Bao 2014, 49(12):1650-1657.

21. Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 2012, 16(5):284-287.

22. Corton JC, Kleinstreuer NC, Judson RS: Identification of potential endocrine disrupting chemicals using gene expression biomarkers. Toxicol Appl Pharmacol 2019, 380:114683.

23. Hossain MA, Amin A, Paul A, Qaisar H, Akula M, Amirpour A, Gor S, Giglio S, Cheng J, Mathew R et al: Recognizing Obesity in Adult Hospitalized Patients: A Retrospective Cohort Study Assessing Rates of Documentation and Prevalence of Obesity. J Clin Med 2018, 7(8).

24. Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS: Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int 2018, 17(1):45-48.

25. Shahoei SH, Nelson ER: Nuclear receptors, cholesterol homeostasis and the immune system. J Steroid Biochem Mol Biol 2019, 191:105364.

26. Luo J, Yang H, Song BL: Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 2020, 21(4):225-245.

27. Boyer JL: Bile formation and secretion. Compr Physiol 2013, 3(3):1035-1078.

28. Zhao L, Zheng X, Liu J, Zheng R, Yang R, Wang Y, Sun L: PPAR signaling pathway in the first trimester placenta from in vitro fertilization and embryo transfer. Biomed Pharmacother 2019, 118:109251.

29. Jiang Y, Li C, Chen L, Wang F, Zhou X: Potential role of retinoids in ovarian physiology and pathogenesis of polycystic ovary syndrome. Clin Chim Acta 2017, 469:87-93.

30. Zhao M, Zhao H, Deng J, Guo L, Wu B: Role of the CLOCK protein in liver detoxification. Br J Pharmacol 2019, 176(24):4639-4652.
31. Sobocanec S, Balog T, Sarić A, Sverko V, Zarković N, Gasparović AC, Zarković K, Waeg G, Macak-Safranko Z, Kusić B et al.: Cyp4a14 overexpression induced by hyperoxia in female CBA mice as a possible contributor of increased resistance to oxidative stress. *Free Radic Res* 2010, 44(2):181-190.

32. Desai BN, Singhal G, Watanabe M, Stevanovic D, Lundasen T, Fisher FM, Mather ML, Vardeh HG, Douris N, Adams AC et al.: Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. *Mol Metab* 2017, 6(11):1395-1406.

33. Cui JY, Klaassen CD: RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. *Biochim Biophys Acta* 2016, 1859(9):1198-1217.

34. Klaassen CD, Liu J, Choudhuri S: Metallothionein: an intracellular protein to protect against cadmium toxicity. *Annu Rev Pharmacol Toxicol* 1999, 39:267-294.

35. Cheng X, Gu J, Klaassen CD: Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes. *Drug Metab Dispos* 2014, 42(11):1826-1833.

36. Meier RPH, Meyer J, Montanari E, Lacotte S, Balaphas A, Muller YD, Clément S, Negro F, Toso C, Morel P et al.: Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner. *Int J Mol Sci* 2019, 20(6).

37. Magee N, Zhang Y: Role of early growth response 1 in liver metabolism and liver cancer. *Hepatoma Res* 2017, 3:268-277.

38. Yamamoto J, Kamata S, Miura A, Nagata T, Kainuma R, Ishii I: Differential adaptive responses to 1- or 2-day fasting in various mouse tissues revealed by quantitative PCR analysis. *FEBS Open Bio* 2015, 5:357-368.

39. Peluso JJ, Liu X, Gawkowska A, Lodde V, Wu CA: Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. *Mol Cell Endocrinol* 2010, 320(1-2):153-161.

40. David CJ, Massagué J: Contextual determinants of TGFβ action in development, immunity and cancer. *Nat Rev Mol Cell Biol* 2018, 19(7):419-435.

41. Zhang P, Kuang H, He Y, Idiga SO, Li S, Chen Z, Yang Z, Cai X, Zhang K, Potthoff MJ et al.: NRG1-Fc improves metabolic health via dual hepatic and central action. *JCI Insight* 2018, 3(5).

42. Oberkofler CE, Limani P, Jang JH, Rickenbacher A, Lehmann K, Raptis DA, Ungethuem U, Tian Y, Grabliauskaite K, Humar R et al.: Systemic protection through remote ischemic preconditioning is spread by platelet-dependent signaling in mice. *Hepatology* 2014, 60(4):1409-1417.

43. Rahman MM, McFadden G: Modulation of NF-κB signalling by microbial pathogens. *Nat Rev Microbiol* 2011, 9(4):291-306.

44. Abe M, Yoshida T, Akiba J, Ikezono Y, Wada F, Masuda A, Sakaue T, Tanaka T, Iwamoto H, Nakamura T et al.: STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury. *World J Gastroenterol* 2017, 23(37):6833-6844.

45. Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y, Zhang J, Xu X, Lin JJ, Zhang BH, Qiu SJ: S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. *Mol Carcinog* 2019, 58(1):19-30.
46. Gao Q, Gu Y, Jiang Y, Fan L, Wei Z, Jin H, Yang X, Wang L, Li X, Tai S et al: Long non-coding RNA Gm2199 rescues liver injury and promotes hepatocyte proliferation through the upregulation of ERK1/2. *Cell Death Dis* 2018, 9(6):602.

47. Mazumder AG, Kumari S, Singh D: Anticonvulsant action of a selective phosphatidylinositol-3-kinase inhibitor LY294002 in pentylentetrazole-mediated convulsions in zebrafish. *Epilepsy Res* 2019, 157:106207.

48. Yan W, Xiaoli L, Guoliang A, Zhonghui Z, Di L, Ximeng L, Piye N, Li C, Lin T: SB203580 inhibits epithelial-mesenchymal transition and pulmonary fibrosis in a rat silicosis model. *Toxicol Lett* 2016, 259:28-34.

49. Wang JZ, Long C, Li KY, Xu HT, Yuan LL, Wu GY: Potent block of potassium channels by MEK inhibitor U0126 in primary cultures and brain slices. *Sci Rep* 2018, 8(1):8808.

50. Eichner J, Kossler N, Wrzodek C, Kalkuhl A, Bach Toft D, Ostenfeldt N, Richard V, Zell A: A toxicogenomic approach for the prediction of murine hepatocarcinogenesis using ensemble feature selection. *PLoS One* 2013, 8(9):e73938.

51. Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM: Soybean Oil Is More Obesogenic and Diabetogenic than Coconut Oil and Fructose in Mouse: Potential Role for the Liver. *PLoS One* 2015, 10(7):e0132672.

52. Kwon EY, Jung UJ, Park T, Yun JW, Choi MS: Luteolin attenuates hepatic steatosis and insulin resistance through the interplay between the liver and adipose tissue in mice with diet-induced obesity. *Diabetes* 2015, 64(5):1658-1669.

53. Seyer P, Vallois D, Poitry-Yamate C, Schütz F, Metref S, Tarussio D, Maechler P, Staels B, Lanz B, Grueter R et al: Hepatic glucose sensing is required to preserve β cell glucose competence. *J Clin Invest* 2013, 123(4):1662-1676.

54. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D: Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. *Cell Metab* 2008, 7(6):520-532.

55. Oishi K, Koyanagi S, Matsunaga N, Kadota K, Ikeda E, Hayashida S, Kuramoto Y, Shimeno H, Soeda S, Ohdo S: Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner. *Mol Pharmacol* 2010, 78(1):135-141.

56. Currie RA, Bombail V, Oliver JD, Moore DJ, Lim FL, Gwilliam V, Kimber I, Chipman K, Moggs JG, Orphanides G: Gene ontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: application to acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. *Toxicol Sci* 2005, 86(2):453-469.
Figure 1

Effect of Hua-Feng-Dan (HFD) and Yaomu (YM) on morphology of liver. Mice received orally YM-0.1, YM-0.3, and HFD-1.2 g/kg for 7 consecutive days, and 24 hr after the last dose, the livers were collected, processed with standard histology, and stained with hematoxylin & eosin, and observed under light microscopy. Magnitude (x 200).
Figure 2

Overview of RNA sequencing results. (A) shows the clustering heatmap of gene expressions from 12 individual samples; (B) shows the heatmap of gene expression from Cont, HFD, YM-01, and YM-0.3 groups. The color brightness is associated with differences in multiples.
Figure 3

Functional enrichment of the differentially expressed genes. (A). GO analysis shows the biological processes involved in differentially Expressed Gene. (B). KEGG shows the signaling pathway involved in differentially Expressed Gene. The size of the dot in the figure represents the number of differential genes that can be annotated in the functional pathway, and the shade of the color represents the significant degree of enrichment of the functional pathway.
Figure 4

Two-dimensional clustering analysis of differentially expressed genes compared to Controls were clustered based on HFD group. YM-H group (1st column 92 DEGs), and YM-L had 235 DEGs (2nd column), HFD had 806 DEGs (3rd column).
Real-time qPCR analysis of 10 selected DEGs. Total RNA was transcribed, and real-time qPCR was performed with the specific primers listed in Supplementary Table 1. Data are mean ± SEM for Control (n = 5), YM-0.1 (n =5), YM-0.3 (n=7), and HFD (n = 5). Data were subjected to Kruskal-Wallis one-way ANOVA, followed by Dunn's multiple comparison test. *Significantly different from Control p < 0.05.
Figure 6

Ingenuity Pathways Analysis (IPA) of upstream regulators based on HFD in Z-score. Red indicates the upregulation, and blue indicates the downregulation.
Figure 7

BaseSpace Correlation Engine (BSCE) analysis of DEGs based on HFD group in $-\log(p\text{-value})$. Red indicates the upregulation, and blue indicates the downregulation. The GSE numbers in Gene Expression Omnibus (GEO) database were included.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 1212SupplementaryTable1DEGs.xlsx